Krystle Vermes

Roche has launched a new HbA1C test to identify diabetes risk and diagnose and monitor patients with diabetes.

Tumor necrosis factor alpha inhibitor can also treat autoimmune diseases such as rheumatoid arthritis and psoriasis.

The FDA has accepted Sandoz's Biologics License Application (BLA) for its proposed etanercept (Enbrel) biosimilar.

Arava can reduce RA symptoms and slow down associated structural damage.

Sanofi has launched a generic version of the rheumatoid arthritis (RA) drug leflunomide (Arava).

The FDA has approved Juviderm Ultra XC for lip augmentation in adults ages 21 or older.

Lixisenatide is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist.

The FDA is considering approval for an intranasal formulation of the opioid overdose antidote naloxone (Narcan).

The FDA is considering approval for Sanofi's lixisenatide type 2 diabetes treatment.

Generic versions of Janssen's Invega atypical antipsychotic are now available from Allergan and Mylan.

The FDA is reviewing a novel treatment for patients with open angle glaucoma or ocular hypertension.

The abbreviations "TPA" and "t-PA" are causing medication mix-ups between alteplase (Activase) and tenecteplase (TNKase).

Pharmacies may now use a test that can detect the flu within 20 minutes.

The FDA is considering a label expansion for Amgen's carfilzomib (Kyprolis) in relapsed multiple myeloma.

Citing a rare yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol (Ultram, Ultram ER, Conzip) in the pediatric population.

A generic version of Novartis' lipid-lowering Lescol XL is now available in the United States.

The FDA is changing dispensing requirements for the schizophrenia drug clozapine (Clozaril) to address safety concerns about severe neutropenia.

The FDA has added an asthma indication to Boehringer Ingelheim's tiotropium bromide inhalation spray (Spiriva Respimat).

Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDLC) from the blood.

The FDA could soon approve a pediatric use for Teva's albuterol sulfate inhalation powder (ProAir RespiClick).

Recalled products were distributed nationwide between November 1, 2014, and September 3, 2015.

Type 2 diabetes drug canagliflozin (Invokana, Invokamet) can decrease bone strength and increase the risk of fractures, the FDA is warning health care professionals.

All non-expired drugs produced for sterile use by Alabama-based compounder Medistat RX have been recalled due to potential contamination, the FDA is warning pharmacists.

Interaction may cause some drugs to lose potency.

An FDA warning about compounded drugs stored in Becton-Dickinson (BD) syringes now applies to 4 more syringe sizes as well as oral syringes.

Mylan has launched a generic equivalent to Bayer's Yasmin birth control tablets.

The FDA has expanded the use of AstraZeneca's blood thinner ticagrelor (Brilinta) in a 60 mg dose for patients with a history of heart attack.

Allergan's ceftaroline fosamil is now approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia with a shorter infusion time.

Secondary hyperparathyroidism can lead to significant clinical consequences.

The first and only patch to provide migraine relief is now available by prescription through specialty pharmacies.